Seizures Market Report 2026

The seizures market size has grown strongly in recent years. It will grow from $4.34 billion in 2025 to $4.6 billion in 2026 at a compound annual growth rate (CAGR) of 6%. The growth in the historic period can be attributed to growing prevalence of epilepsy, improved diagnostic awareness, availability of anti-epileptic drugs, rise in healthcare spending, technological advances in EEG devices.

The seizures market size is expected to see strong growth in the next few years. It will grow to $5.75 billion in 2030 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to AI-enabled seizure prediction tools, remote patient monitoring adoption, personalized therapy solutions, expansion of neurology-focused telehealth, novel neurostimulation devices. Major trends in the forecast period include wearable seizure monitoring devices, home-based EEG solutions, AI-driven seizure prediction, tele-neurology consultations, integration with health apps.

The rising prevalence of traumatic brain injuries is expected to drive the growth of the seizures market in the coming years. Traumatic brain injuries (TBI) refer to damage to the brain caused by a sudden external force, such as a blow, jolt, or penetrating injury to the head. The incidence of TBIs is increasing due to the growing number of road accidents, as high-speed collisions and distracted driving often result in severe head injuries. Seizures can act as an early indicator of traumatic brain injuries, enabling physicians to diagnose and manage underlying brain damage more effectively. For example, in October 2023, the World Federation of Neurology, a UK-based organization dedicated to advancing neurological research and practice worldwide, reported that more than 40% of the global population is affected by a neurological condition, a figure expected to nearly double by 2050. Thus, the increasing prevalence of traumatic brain injuries is fueling the growth of the seizures market.

Key companies in the seizures market are developing innovative solutions, such as buccal film, to improve treatment accessibility and patient adherence. Buccal film is a thin, dissolvable strip placed against the inner lining of the cheek (buccal mucosa), allowing the drug to be absorbed directly into the bloodstream. For instance, in December 2024, Aquestive Therapeutics Inc., a US-based pharmaceutical company, received U.S. FDA orphan drug exclusivity for Libervant (diazepam) buccal film, intended for pediatric patients aged two to five experiencing seizure clusters. This formulation offers a non-invasive, easy-to-administer alternative to traditional diazepam methods, enabling rapid absorption through the buccal mucosa for quicker onset of action. As the first and only orally administered diazepam film approved for this age group, Libervant aims to enhance caregiver convenience and patient compliance. This exclusivity further strengthens Aquestive’s position in advancing oral film-based epilepsy therapies.

In April 2024, Harmony Biosciences, a US-based biopharmaceutical company, acquired Epygenix Therapeutics for an undisclosed amount. Through this acquisition, Harmony Biosciences aims to expand its epilepsy pipeline by acquiring EPX‑100, a lead candidate for Dravet syndrome and Lennox‑Gastaut syndrome, thereby deepening its focus on the seizure treatment market. Epygenix Therapeutics is a US-based precision-medicine biopharma company developing therapies for rare genetic epilepsies.

Major companies operating in the seizures market are Johnson & Johnson Service Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., UCB S.A., Eisai Co. Ltd., H. Lundbeck A S, Zydus Lifesciences Limited, SK Biopharmaceuticals Co. Ltd., Supernus Pharmaceuticals Inc., Taro Pharmaceutical Industries Ltd., Marinus Pharmaceuticals Inc., Eton Pharmaceuticals Inc., Sunovion Pharmaceuticals Inc., Pfizer Inc., Abbott Laboratories, Cipla Limited, Dr Reddy’s Laboratories Ltd., Aurobindo Pharma Limited.

North America was the largest region in the seizures market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the seizures market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the seizures market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have created challenges for the seizures market by increasing the cost of imported anti-epileptic drugs, pharmaceutical ingredients, and drug-delivery devices used in oral, parenteral, and topical therapies. Regions such as Asia-Pacific and parts of Europe that rely on international pharmaceutical supply chains have been most affected, leading to higher medication prices for hospitals, clinics, and patients. These higher costs can limit access to newer second- and third-generation anti-epileptic therapies in cost-sensitive markets. At the same time, tariffs are encouraging local drug manufacturing and regional formulation facilities, which is gradually improving supply stability and long-term affordability in the seizures market.

The seizures market research report is one of a series of new reports that provides seizures market statistics, including seizures industry global market size, regional shares, competitors with a seizures market share, detailed seizures market segments, market trends and opportunities, and any further data you may need to thrive in the seizures industry. This seizures market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Seizures are sudden, uncontrolled bursts of electrical activity in the brain that can cause changes in movement, behavior, sensation, or awareness. They result from abnormal neuronal activity and may be triggered by epilepsy, head injuries, infections, or other medical conditions.

The main drug categories for seizures include first-generation anti-epileptics, second-generation anti-epileptics, and third-generation anti-epileptics. First-generation anti-epileptic drugs (AEDs) represent the earliest class of medications developed to treat epilepsy. These drugs can be administered via oral, parenteral, and topical routes. They are distributed through hospital pharmacies, independent pharmacies, and online pharmacies, and are utilized by a variety of end-users, including hospitals and clinics, ambulatory surgical centers, homecare settings, and others.

The seizures market consists of sales of neurostimulation devices, wearable seizure detection devices, and medical cannabis products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.